Statin use and cognitive function in middle-aged adults with type 1 diabetes

Table 3 Select characteristics¹ of middle-aged adults with childhood-onset type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study, by cognitive impairment status

	Cognitively normal (n = 78)	Cognitively impaired (n = 30)	P value
Data are n (%), mean ± SD, or median (IQR)
Coronary artery disease2	9 (12%)	9 (30%)	0.02
Cardio-metabolic risk factors
Ever using statins (1986-2013)3	34 (44%)	23 (77%)	0.003
Duration of statin use (statin years)3	0 (0-6)	7 (2-8)	0.002
If statin use, only used lipophilic statin3	30 (88%)	21 (91%)	0.99
Study average LDLc (mg/dL)3	104.5 ± 25.8	115.9 ± 24.8	0.06
History of high blood pressure4	26 (33%)	13 (43%)	0.24
Brain imaging
Severe White Matter Hyperintensities5	17 (26%)	11 (46%)	0.09
Left hippocampal volume6	0.31 ± 0.03	0.31 ± 0.03	0.31

Reported P value is adjusted for education. ¹Relationships between other factors and cognitive impairment in this type 1 diabetes cohort have been previously described and published elsewhere (for details, see Nunley et al[18], 2015);

²Assessed in 2004-2006;

³Assessed since EDC baseline (1986-1988) through time of cognitive testing (2010-2013);

⁴Defined as any EDC assessed SBP > 140 mmHg or DBP > 90, or ever self-reported use of anti-hypertensive medication from 1986-1988 through 2010-2013;

⁵Fazekas rating 2-3 vs Fazekas rating 1; data on n = 89 (for details, see Nunley et al[28], 2015);

⁶Hippocampal volume as a percentage of total intracranial volume, data on n = 88 (for details, see Hughes et al[26], 2013). Measures assessed 2010-2013 unless otherwise noted. LDLc: Low density lipoprotein cholesterol.